Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NuVim, Innovative Technologies merge

This article was originally published in The Tan Sheet

Executive Summary

Paramus, N.J.-based nutritional firm NuVim signed a letter of intent to merge with supplement firm Innovative Technologies Corporation of America, NuVim says Aug. 20. Combined, annual gross revenues total approximately $5 million and under the terms, NuVim will have sales and distribution rights to market ITCA's hangover product Hair of the Dog worldwide. NuVim will "issue debt to finance the cash portion of the merger" and once completed, the merger will operate under the name NuVim. Tampa-based ITCA will receive $2.3 million cash and 4.25 million shares of "restricted common stock in the tax free reorganization," firm says

You may also be interested in...

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

Coronavirus Update: Pfizer Urged To Delay Vaccine Submission

A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert Bourla.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts